Reported Late Wednesday, Atara Biotherapeutics And Pierre Fabre Laboratories Announced The Publication Of Phase 3 ALLELE Tab-Cel® Data In The Lancet Oncology
Portfolio Pulse from Benzinga Newsdesk
Atara Biotherapeutics and Pierre Fabre Laboratories announced the publication of Phase 3 ALLELE Tab-Cel data in The Lancet Oncology, showing a 51.2% objective response rate and a median duration of response of 23.0 months in patients with relapsed or refractory EBV+ PTLD. The U.S. BLA submission is planned for Q2 2024 based on these positive results.
February 01, 2024 | 8:17 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Atara Biotherapeutics' positive Phase 3 results for Tab-Cel could bolster investor confidence, with a strong clinical file supporting a planned BLA submission in Q2 2024.
The publication of positive Phase 3 data typically has a favorable impact on a biotech company's stock price as it validates the efficacy of the therapy and brings the product closer to potential market approval and commercialization. The strong clinical file and planned BLA submission indicate progress in the drug's development pipeline, which is a critical factor for investors in the biotech sector.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100